Increased tumour marker concentrations in patients with pericardial effusion with anti-inflammatory treatment

Trapé, Jaume; Guiteres, Pere; Roca, Jordi; Reig, J.P.; Montesinos, J.; Franquesa, Josefina

doi:10.3109/00365513.2014.924157

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several pharmacological treatments have been associated with increased CA 72-4 concentrations. In patients with pericardial effusion treated with ibuprofen, a notable increase in CA 72-4 concentrations was observed, exceeding the URL by more than ten times, which then fell after the discontinuation of the treatment [94]. Treatment with corticosteroids and proton pump inhibitors has also been identified as a potential cause of elevated CA 72-4 concentrations [95].…”

Section: Cancer Antigen Ca 72-4 (Ca 72-4)mentioning

confidence: 99%

Factors influencing blood tumor marker concentrations in the absence of neoplasia

Trapé,

Fernández-Galán,

Auge

et al. 2024

TUB

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Tumor markers (TMs) are a heterogeneous group of molecules used in the diagnosis, prognosis and follow-up of cancer patients. During neoplastic differentiation, cells can either directly synthesize or induce the synthesis of TMs, and the release of these molecules into the bloodstream allows their quantification in biological fluids. Although very small concentrations of TMs are usually present in the serum or plasma of healthy subjects, increased concentrations may also be found in the presence of benign diseases or due to technical interference, producing false positive results. MATERIAL AND METHODS AND RESULTS: Our review analyses the causes of false positives described between January 1970 to February 2023 for the TMs most frequently used in clinical practice: α-fetoprotein (AFP), β2-microglobulin (β2-M), cancer antigen 15-3 (CA 15-3), cancer antigen CA 19-9 (CA 19-9), cancer antigen CA 72-4 (CA 72-4), cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), chromogranin A (CgA), choriogonadotropin (hCG), cytokeratin 19 fragment (CYFRA 21-1), neuron-specific enolase (NSE), human epididymis protein 4 (HE4), serum HER2 (sHER2), squamous cell carcinoma antigen (SCCA), protein induced by vitamin K absence-II (PIVKA-II), Pro-gastrin-releasing peptide (Pro-GRP), prostate-specific antigen (PSA), Protein S-100 (S-100) and thyroglobulin (Tg). A total of 247 references were included. CONCLUSIONS: A better understanding of pathophysiological processes and other conditions that affect the concentration of TMs might improve the interpretation of results and their clinical application.

show abstract

Section: Cancer Antigen Ca 72-4 (Ca 72-4)mentioning

confidence: 99%